Oct 26, 2021

VIRALEZE™ distribution and supply to Vietnam (ASX Announcement)

VIRALEZE™ distribution and supply to Vietnam (ASX Announcement)
  • Starpharma has received its first orders of approximately 100,000 units of VIRALEZE™ antiviral nasal spray to Vietnam, with product expected to arrive in Vietnam in November
  • Registration of VIRALEZE™ in Vietnam is already well advanced
  • Vietnam is experiencing a widespread Delta outbreak with ~20% of its population fully vaccinated
  • A portion of VIRALEZE™ from these initial orders will be donated to hospitals and healthcare organisations in Vietnam
  • VIRALEZE™ is a broad-spectrum antiviral nasal spray that contains SPL7013, which has been shown to have potent antiviral and virucidal activity in multiple respiratory viruses, including inactivation of >99.9% of the Delta variant of SARS-CoV-2, in laboratory studies

Melbourne, Australia; 26 October 2021: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced it has signed an initial supply contract for VIRALEZE™ antiviral nasal spray in Vietnam and first delivery into Vietnam is expected in early November. In parallel with completing registration, Starpharma is finalising an ongoing distribution agreement for VIRALEZE™ in Vietnam which will allow subsequent larger orders and ongoing supply.

Vietnam, which has a population of approximately 97 million, is experiencing a significant Delta outbreak with ~20 per cent of its population fully vaccinated[1]. According to figures from the World Health Organisation, the death toll in Vietnam from COVID-19 exceeds 21,000[2].

Starpharma’s initial orders committed for purchase under this initial supply distribution contract for VIRALEZE™ to Vietnam total approximately 100,000 units of VIRALEZE™ with further larger orders expected upon signing of an ongoing distribution agreement, which is currently being finalised. The distribution arrangements for Vietnam include Australian-based Healthco Australia Pty Ltd (HealthCo), with Truong Bao Land International Investment Company Limited (TBL) responsible for importation, sales, marketing, and distribution in Vietnam. TBL will also utilise the local medical distribution networks in Vietnam of associated company Nam Thanh Trade and Medical Services Company Limited[3]. The initial supply contract for the first shipments of VIRALEZE™ has a maximum three-month term and will be replaced by an ongoing distribution arrangement, which is currently being finalised. These arrangements are exclusive for retail, pharmacies, clinics, and hospitals in Vietnam.

The first shipment of VIRALEZE™ is expected in Vietnam in early November 2021 and launch preparations for the product are already well advanced with promotions to start shortly. A portion of VIRALEZE™ from these orders will be donated to hospitals and other healthcare organisations in Vietnam.

Under the initial contract, Starpharma will supply VIRALEZE™, with TBL responsible for sales, distribution, and marketing of the product locally in Vietnam. Registration of VIRALEZE™ in Vietnam is already well advanced with full registration expected in the coming weeks following the final listing step.

Dr Jackie Fairley, Starpharma CEO commented: “We are very pleased to be able to make VIRALEZE™ available to Vietnamese consumers and frontline workers next month, especially given the current Delta outbreak and vaccination rates in Vietnam. This supply contract is one of a number of international commercial arrangements for VIRALEZE™ being negotiated by Starpharma and we look forward to making further announcements about those soon.”

VIRALEZE™ is a broad-spectrum antiviral nasal spray. The antiviral agent in VIRALEZE™, referred to as SPL7013, has been shown to have potent antiviral and virucidal activity in multiple respiratory viruses and multiple variants of SARS-CoV-2, including inactivation of >99.9% of the highly infectious Delta variant, in laboratory studies. VIRALEZE™ is applied in the nose to provide a physical barrier - between viruses and the nasal mucous membrane - that traps and irreversibly inactivates virus.

VIRALEZE™ is registered in Europe and India, and available online in certain markets. VIRALEZE™ is partnered with LloydsPharmacy in the UK, ADMENTA Italia Group in Italy, and Starpharma is in advanced discussions with potential commercial partners elsewhere in Europe, Asia, India, and other regions. VIRALEZE™ is not registered for sale or supply in Australia.

VIRALEZE Antiviral Nasal Spray

VIRALEZE™ contains SPL7013, which has been shown in laboratory studies to inactivate a broad spectrum of respiratory/cold viruses, including multiple SARS-CoV-2 variants, influenza, and RSV. VIRALEZE™ is registered for sale in Europe and India. VIRALEZE™ is not registered for sale or supply in Australia.

SPL7013 is also included in other products registered in >45 countries and available for sale in the UK, Europe, Japan, South East Asia, Australia and New Zealand.

Starpharma acknowledges the $1 million in funding for the development of VIRALEZE provided by the Australian Government’s Medical Research Future Fund (MRFF) Biomedical Translation Bridge (BTB) Program, with support from UniQuest. Delivered by MTPConnect, the Australian Government's BTB program is a $22.3 million MRFF initiative that provides up to $1 million in matched funding to nurture the translation of new therapies, technologies and medical devices through to proof of concept to turn innovative medical ideas into reality.

Download ASX Announcement: VIRALEZE™ distribution and supply to Vietnam (PDF 224kb)

[1] https://covidvax.live/location/vnm

[2] https://covid19.who.int/region/wpro/country/vn

[3] NAM THANH MEDICAL CO., LTD (short name: NAMTHANH MSATCO; Business Registration Certificate No: 0107308573) is a supplier of medical products and equipment, including rapid COVID-19 test kits, based in Vietnam.

 This contains certain forward-looking statements.